FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2808295405> ?p ?o ?g. }

• W2808295405 abstract "Background The retention rates (RR) of biological therapies (BT) have been extensively studied in European countries and the United States, but there is a lack of information about them in emerging populations. Objectives To analyse BT retention rates and variables associated to them at the BIOBADAGUAY registry Methods Patients with a chronic inflammatory arthritis enrolled in the Paraguayan-Uruguayan biological register (BIOBADAGUAY) between2015 and 2017 where included in the study. Phase I of the study was focused in the global RR analysis and association with clinical and epidemiological variables. In phase II we analysed BT retention rate according to different discontinuation motives and association with clinical and epidemiological variables. Survival analysis was performed using Kaplan-Meier estimators and proportional hazard regression models Results A total of 778 BTs where included in the study (etanercept n=184, adalimumab n=440, rituximab n=44, infliximab n=27, tocilizumab n=75, and others n=8). The underlying diagnosis associated to these BTs were rheumatoid arthritis (RA;58.2%), juvenile arthritis (JIA; 14.2%), ankylosing spondylitis (SA; 12.5%) and psoriatic arthritis (PA; 8,0%). In phase I we found that mean survival times were 322 (±17.9), 315 (±22.32), 289(±8.52) and 233 (±16.69) weeks for AS, PA, RA and JIA respectively. The survival association analysis has shown that JIA diagnosis (p=2.26 × 10–4, HR=1.80 [95%CI, 1.32–2.46]), corticosteroids (p=1.54 × 10–2, HR=1.38 [95% CI, 1.06–1.79]), and previous BT (p=3.32 × 10–2, HR=1.43 [95% CI, 1.03–1.98]) were variables significantly associated with a lower BT retention. In phase II, we stratified the survival analysis by cause of discontinuation. We found that corticoids (p=9.48 × 10–4 HR=2.02 [95% CI, 1.33–3.06]), female gender (p=4.36 × 10–2, HR=1.66 [95% CI, 1.01–2.72]) and previous BT (p=2.56 × 10–2, HR=1.72 [95% CI, 1.07–2.78]) were associated with lower BT retention due to inefficacy. When we analysed withdrawn according to adverse events, we found that RA (p=02,80 × 10–2, HR=1,83[IC 95% 1,07–3,15]), previous BT (p=4,83 × 10–2, HR=1,76[IC 95% 1,00–3,09]) and age (p=7,14 × 10–5, HR=1,05 [IC 95% 1,02–1,05]) were significantly associated with therapy discontinuation. In the group of treatments with discontinuation due to remission, we found that JIA diagnosis (p=7,93 × 10–8, HR=30,58 [IC 95% 8,77–106,71]), age (p=7,83 × 10–6, HR 0,83[IC 95% 0,76–0,90]) and gender (p=4,36 × 10–2, HR 1,66[IC 95% 1,01–2,72]) were associated to discontinuation due to remission. Conclusions Our results show that different sets of clinical and demographical variables are significantly associated to biological therapy survival depending on the discontinuation cause. Disclosure of Interest None declared" @default.
• W2808295405 created "2018-06-21" @default.
• W2808295405 creator A5003464272 @default.
• W2808295405 creator A5009978818 @default.
• W2808295405 creator A5012145196 @default.
• W2808295405 creator A5025488398 @default.
• W2808295405 creator A5028592352 @default.
• W2808295405 creator A5032553679 @default.
• W2808295405 creator A5034226700 @default.
• W2808295405 creator A5040051035 @default.
• W2808295405 creator A5040603924 @default.
• W2808295405 creator A5050789625 @default.
• W2808295405 creator A5057339688 @default.
• W2808295405 creator A5064257214 @default.
• W2808295405 creator A5072268449 @default.
• W2808295405 creator A5085138316 @default.
• W2808295405 date "2018-06-01" @default.
• W2808295405 modified "2023-09-26" @default.
• W2808295405 title "AB0453 Biological therapies retention rate in two sudamerican countries. data from biobadaguay registry" @default.
• W2808295405 doi "https://doi.org/10.1136/annrheumdis-2018-eular.6109" @default.
• W2808295405 hasPublicationYear "2018" @default.
• W2808295405 type Work @default.
• W2808295405 sameAs 2808295405 @default.
• W2808295405 citedByCount "0" @default.
• W2808295405 crossrefType "proceedings-article" @default.
• W2808295405 hasAuthorship W2808295405A5003464272 @default.
• W2808295405 hasAuthorship W2808295405A5009978818 @default.
• W2808295405 hasAuthorship W2808295405A5012145196 @default.
• W2808295405 hasAuthorship W2808295405A5025488398 @default.
• W2808295405 hasAuthorship W2808295405A5028592352 @default.
• W2808295405 hasAuthorship W2808295405A5032553679 @default.
• W2808295405 hasAuthorship W2808295405A5034226700 @default.
• W2808295405 hasAuthorship W2808295405A5040051035 @default.
• W2808295405 hasAuthorship W2808295405A5040603924 @default.
• W2808295405 hasAuthorship W2808295405A5050789625 @default.
• W2808295405 hasAuthorship W2808295405A5057339688 @default.
• W2808295405 hasAuthorship W2808295405A5064257214 @default.
• W2808295405 hasAuthorship W2808295405A5072268449 @default.
• W2808295405 hasAuthorship W2808295405A5085138316 @default.
• W2808295405 hasBestOaLocation W28082954051 @default.
• W2808295405 hasConcept C10515644 @default.
• W2808295405 hasConcept C107130276 @default.
• W2808295405 hasConcept C126322002 @default.
• W2808295405 hasConcept C207103383 @default.
• W2808295405 hasConcept C2776260265 @default.
• W2808295405 hasConcept C2777077863 @default.
• W2808295405 hasConcept C2777138892 @default.
• W2808295405 hasConcept C2777178219 @default.
• W2808295405 hasConcept C2777226972 @default.
• W2808295405 hasConcept C2777402515 @default.
• W2808295405 hasConcept C2777575956 @default.
• W2808295405 hasConcept C2778715236 @default.
• W2808295405 hasConcept C2779134260 @default.
• W2808295405 hasConcept C2780132546 @default.
• W2808295405 hasConcept C2781290027 @default.
• W2808295405 hasConcept C44249647 @default.
• W2808295405 hasConcept C50382708 @default.
• W2808295405 hasConcept C71924100 @default.
• W2808295405 hasConceptScore W2808295405C10515644 @default.
• W2808295405 hasConceptScore W2808295405C107130276 @default.
• W2808295405 hasConceptScore W2808295405C126322002 @default.
• W2808295405 hasConceptScore W2808295405C207103383 @default.
• W2808295405 hasConceptScore W2808295405C2776260265 @default.
• W2808295405 hasConceptScore W2808295405C2777077863 @default.
• W2808295405 hasConceptScore W2808295405C2777138892 @default.
• W2808295405 hasConceptScore W2808295405C2777178219 @default.
• W2808295405 hasConceptScore W2808295405C2777226972 @default.
• W2808295405 hasConceptScore W2808295405C2777402515 @default.
• W2808295405 hasConceptScore W2808295405C2777575956 @default.
• W2808295405 hasConceptScore W2808295405C2778715236 @default.
• W2808295405 hasConceptScore W2808295405C2779134260 @default.
• W2808295405 hasConceptScore W2808295405C2780132546 @default.
• W2808295405 hasConceptScore W2808295405C2781290027 @default.
• W2808295405 hasConceptScore W2808295405C44249647 @default.
• W2808295405 hasConceptScore W2808295405C50382708 @default.
• W2808295405 hasConceptScore W2808295405C71924100 @default.
• W2808295405 hasLocation W28082954051 @default.
• W2808295405 hasOpenAccess W2808295405 @default.
• W2808295405 hasPrimaryLocation W28082954051 @default.
• W2808295405 hasRelatedWork W1836932992 @default.
• W2808295405 hasRelatedWork W1969969925 @default.
• W2808295405 hasRelatedWork W2021281275 @default.
• W2808295405 hasRelatedWork W2028955920 @default.
• W2808295405 hasRelatedWork W2319067587 @default.
• W2808295405 hasRelatedWork W2333719876 @default.
• W2808295405 hasRelatedWork W2363397485 @default.
• W2808295405 hasRelatedWork W2415291454 @default.
• W2808295405 hasRelatedWork W2461782422 @default.
• W2808295405 hasRelatedWork W2550965354 @default.
• W2808295405 hasRelatedWork W2565641385 @default.
• W2808295405 hasRelatedWork W2580358133 @default.
• W2808295405 hasRelatedWork W2754289805 @default.
• W2808295405 hasRelatedWork W2756030839 @default.
• W2808295405 hasRelatedWork W2791850181 @default.
• W2808295405 hasRelatedWork W2914994266 @default.
• W2808295405 hasRelatedWork W2985909340 @default.
• W2808295405 hasRelatedWork W3005887226 @default.
• W2808295405 hasRelatedWork W3197123363 @default.
• W2808295405 hasRelatedWork W2442295132 @default.
• W2808295405 isParatext "false" @default.

• next